Personal profile
Public Profile
I am a passionate biomedical researcher with an emerging international reputation and leadership in chronic myeloid leukaemia (CML). I am investigating new therapies for curing CML patients, collaborating with clinicians and associations of patients. Originally from a small town in the Northern Italy, called Corgeno, I relocated to Adelaide 7 years ago to join the laboratory of Professor Timothy Hughes at the South Australian Health and Medical Research Institute, SAHMRI. I met Professor Hughes and A/Prof David Ross for the first time in 2013 at the Annual Conference of the American Society of Haematology, ASH, the most important Conference for the haematologists worldwide. As winner of the Abstract Achievement Award, I was presenting my work on minimal residual disease on CML done on my laboratory in Italy. This was the beginning of an adventure that changed my life. After this first meeting, I was invited at SAHMRI as visiting post-doc, and 7 years later I am now a permanent resident, with an established friendship circle, a competitive river rower and a Surf Life Saver! I am also President of the Association of Italian Researchers in Australasia, ARIA. Under my Presidency the Association expanded from South Australia to all Australia, New Zealand and Pacific Islands. I am working closely with the Italian Government for promoting the work of Italian and Italo/Australian researchers in Australia and New Zealand, I am collaborating with the Australian Government for promoting culture and increasing the awareness about health and research in Australia, and I am mediating collaborations of research between the Italian and Australian Governments. I am currently co-writing a book about Scientific Italian migration in Australia.
I am a passionate science communicator concerned with giving back to the next generation of scientists and sharing the significance of my findings with the public. I am advocate for the women rights, and Founder of ARIA Women, a subgroup of ARIA aimed to empower women in Academia.
I specialised in medical genetics, completing my studies with honours in 2016. I used my expertise in genetic diseases and DNA mutations to develop leading edge technologies for studying mitochondrial DNA mutations and monitoring minimal residual disease in CML patients. In 2019, in a highly competitive global competition, I was awarded the inaugural international John Goldman Research Award. As Principal Investigator I am currently leading a team of researchers in a ground-breaking work, aiming to develop a model of prediction of treatment-free remission, currently no available in clinical practice. I clarified the identification of CML patients who may be able to achieve remission, safely discontinue their therapy, and therefore be considered cured.
Also that year, I received a prestigious Beat Cancer Project Mid-Career Research Fellowship from Cancer Council SA allowing me to further the understanding of the metabolism of CML stem cells. My aim is to develop targeted therapies for eradicating leukaemic stem cells and cure CML patients.
Education/Academic qualification
The genomic landscape of mitochondrial DNA mutations in Chronic Myeloid Leukaemia, University of Milan
2012 → 2016
Award Date: 9 Nov 2016
PhD, p53 family members regulate the Otx1 gene expression in differentiation of breast cancer stem cells and in mammary gland development, University of Insubria
2007 → 2012
Award Date: 23 Feb 2012
External positions
Affiliate Senior Lecturer, University of Adelaide
Oct 2020 → Nov 2023
Affiliated Lecturer, University of Adelaide
1 Nov 2017 → 2020
Collaborations and top research areas from the last five years
-
Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia
Naderi, Z., Sadras, T., Branford, S., Shanmuganathan, N. & Pagani, I. S., Dec 2026, In: Current Hematologic Malignancy Reports. 21, 1, 11.Research output: Contribution to journal › Review article › peer-review
-
Lipid Storage and Therapy Resistance in Chronic Myeloid Leukaemia: A Novel Perspective on Targeting Metabolic Vulnerabilities
Tolland, M., Ross, D. M., White, D., Hughes, T. P. & Pagani, I. S., Sept 2025, In: Cancers. 17, 18, 3033.Research output: Contribution to journal › Review article › peer-review
Open Access1 Link opens in a new tab Citation (Scopus) -
Modulation of energetic and lipid pathways by curcumin as a potential chemopreventive strategy in human prostate cancer cells
Pellegrino, M., Occhiuzzi, M. A., Grande, F., Pagani, I. S., Aquaro, S. & Tucci, P., 26 Nov 2024, In: Biochemical and Biophysical Research Communications. 735, 150477.Research output: Contribution to journal › Article › peer-review
Open AccessFile4 Link opens in a new tab Citations (Scopus)84 Downloads (Pure) -
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention
Shanmuganathan, N., Wadham, C., Shahrin, N. H., Feng, J., Thomson, D., Wang, P., Saunders, V., Kok, C. H., King, R. M., Kenyon, R. R., Lin, M., Pagani, I. S., Ross, D. M., Yong, A. S. M., Grigg, A. P., Mills, A. K., Schwarer, A. P., Braley, J., Altamura, H. & Yeung, D. T. & 4 others, , Sept 2023, In: Haematologica. 108, 9, p. 2380-2395 16 p.Research output: Contribution to journal › Article › peer-review
Open Access23 Link opens in a new tab Citations (Scopus) -
Italian–Australian Scientific and Research Cooperation
Pagani, I. S. & Torresi, T., 1 Jan 2023, Italy and Australia Redefining Bilateral Relations for the Twenty-First Century. Springer Nature, p. 241-265 25 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review
Prizes
-
American Society of Hematology (ASH) International Post-doctoral Fellow (IPDF) approval and $500 ASH Abstract Achievement Award
Pagani, I. (Recipient) & Pagani, I. (Recipient), 2013
Prize
-
-
-
-
Activities
-
Association of Italian Researchers in Australasia, ARIA (External organisation)
Pagani, I. (Chair)
1 Feb 2024Activity: Membership › Membership of board
-
Australian CML Association, CMLa (External organisation)
Pagani, I. (Chair)
1 Mar 2024Activity: Membership › Membership of network
-
Treatment Free Remission: MRD Studies.
Pagani, I. (Invited speaker)
17 Oct 2024 → 18 Oct 2024Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks
-
New Directions in Leukaemia Research
Pagani, I. (Member of programme committee)
4 Mar 2024 → 6 Mar 2024Activity: Participating in or organising an event › Participation in workshop, seminar, course
-
Tyrosine kinase inhibitor-responsive chronic myeloid leukaemia is associated with reduced OXPHOS capacity and mtDNA mutations likely contribute to this.
Pagani, I. (Speaker)
15 May 2024 → 17 May 2024Activity: Invited talks and oral presentations › Invited Keynote and Plenary Presentations